Cozaar

HTN. Reduce risk of CV morbidity & mortality in hypertensive patients w/ left ventricular hypertrophy. Renal protection in type 2 diabetic patients w/ proteinuria.

HTN Usual starting & maintenance dose: 50 mg once daily. May be increased to 100 mg once daily. Patient w/ intravascular vol-depletion Initially 25 mg once daily. Reduction of risk of CV morbidity & mortality in hypertensive patients w/ left ventricular hypertrophy Initially 50 mg once daily. Add low dose hydrochlorothiazide &/or increase dose to 100 mg once daily based on BP response. Renal protection in type 2 diabetic patients w/ proteinuria Initially 50 mg once daily. May be increased to 100 mg once daily based on BP response.

May be taken with or without food.

Hypersensitivity. Concomitant use w/ aliskiren in patients w/ diabetes. Pregnancy.

Discontinue treatment if angioedema including swelling of larynx & glottis (causing airway obstruction) &/or face, lips, pharynx &/or tongue occurs; oligohydramnios is observed. Symptomatic hypotension in patients who are intravascularly vol-depleted (eg, those treated w/ high-dose diuretics). Electrolyte imbalances in patients w/ renal impairment w/ or w/o diabetes. Increased plasma conc in cirrhotic patients. Lethargy, nausea, vomiting. Black patients. Correct symptomatic hypotension prior to therapy. Closely monitor renal function & serum K. Not recommended to use concomitantly w/ K-supplement or K-sparing diuretics. History of hepatic impairment. Not recommended to use in patients w/ renal impairment (serum creatinine >3-4 mg/dL). Fetal toxicity including oligohydramnios associated w/ fetal lung hypoplasia & skeletal deformations. Increased risk to fetus during 2nd or 3rd trimesters of pregnancy. Perform serial ultrasound exam to assess intra-amniotic environment. Discontinue treatment when pregnancy is detected. Lactation. Closely observe infants w/ history of in utero exposure for hypotension, oliguria, & hyperkalemia.

Abdominal pain, asthenia/fatigue, chest pain, edema/swelling; palpitation, tachycardia; diarrhea, dyspepsia, nausea; back pain, muscle cramps; dizziness, headache, insomnia; cough, nasal congestion, pharyngitis, sinus disorder, upper resp infection; vertigo; hypotension, hyperkalemia. Liver function abnormalities, vomiting; malaise; anemia; myalgia, arthralgia; migraine, dysgeusia; erectile dysfunction/impotence; urticaria, pruritus, erythroderma, photosensitivity.

Reduced levels of active metabolite w/ rifampin & fluconazole. Increased serum K w/ K-sparing diuretics (eg, spironolactone, triamterene, amiloride), K supplements or K-containing salt substitutes, or other drugs increasing serum K (eg, trimethoprim-containing products). Reduced lithium excretion w/ lithium salts. Attenuated antihypertensive effects & further renal function deterioration w/ NSAIDs including selective COX-2 inhibitors. Co-administration w/ aliskiren. Reduced therapeutic effect w/ grapefruit juice.

Angiotensin II Antagonists

C09CA01 - losartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

D